Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ digital
    • Subscribe to CMAJ print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ digital
    • Subscribe to CMAJ print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Letters

Anaphylaxis treatment: the details

Anne K. Ellis and James H. Day
CMAJ November 25, 2003 169 (11) 1148-1149;
Anne K. Ellis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James H. Day
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Axel Ellrodt raises several questions regarding discharge therapy after anaphylaxis. The first relates to alternatives to diphenhydramine prophylaxis. Diphenhydramine has been established as an effective agent in the treatment and prevention of anaphylactic and anaphylactoid reactions, where its sedative properties are an advantage.1 Given orally at doses of 25 to 50 mg every 4 to 6 hours, it remains the antihistamine of choice to prevent and manage these episodes. A second-generation antihistamine could be substituted if sedation were a concern. However, because biphasic reactivity may be delayed for up to 24 hours, the patient should be advised to minimize activity (including driving) during this interval, and sedative effects may therefore be unimportant. After this interval, treatment with either diphenhydramine or a nonsedating antihistamine such as cetirizine (10 mg daily for 3 days, given orally) would be appropriate. Although H2 receptors are involved to a limited extent in the pathophysiology of anaphylaxis, we rarely administer H2 blockers in this capacity and consider their use optional. With respect to prophylactic corticosteroids, we usually begin with a single oral dose of 50 mg prednisone, followed by reduced doses of 40 mg on days 2 and 3, then 20 mg on days 4 and 5, then discontinuation. The medication is given in the morning to optimize effect and minimize adrenocortical suppression.

The questions surrounding cross-reactivity of penicillin and third-generation cephalosporins remain unresolved. Allergic reactivity to cephalosporins (of any type) is 4 to 8 times greater in patients with a history of allergy to penicillin than in those without,2,3 and the rate of reactivity to cephalosporins is 4% to 7% in patients with previous reactivity to penicillin.3 Recent evidence suggests that variable side-chains on the β-lactam ring, rather than the β-lactam nucleus, induce this cross-reactivity.4,5 Indeed, several patients with documented skin test reactivity to penicillin who were given doses of second- and third-generation cephalosporins had no reactivity.6 Nevertheless, caution is advised in the administration of cephalosporins to patients with known anaphylactic reactivity to penicillin.

We agree that the designation 1:1000 or 1:10 000 can be confusing, but this description facilitates rapid dosing and administration of epinephrine, which is essential in managing anaphylaxis.7 In addition, this presentation displays the dilution much more prominently than if the dose is given as milligrams per millilitre (mg/mL).

Patrick Potter raises the issue of empiric use of glucagon for treatment-resistant anaphylaxis. Epinephrine resistance in anaphylaxis does suggest concomitant β-blockade and hence an indication for glucagon administration. However, glucagon may be associated with nausea, vomiting, hyperglycemia and allergic reactivity, which precludes its general use in anaphylaxis. If repeat doses of epinephrine yield inadequate clinical response during an episode of anaphylaxis, especially when there is evidence of increasing systolic hypertension due to unopposed α-adrenergic activation and bradycardia signifying reflex vagotonic effect, further epinephrine is contraindicated and glucagon should be administered.

Anne K. Ellis James H. Day Division of Allergy Kingston General Hospital Kingston, Ont.

Footnotes

  • Competing interests: None declared.

References

  1. 1.↵
    Kelly JF, Patterson R, Lieberman P, Mathison DA, Stevenson DD. Radiographic contrast media studies in high risk patients. J Allergy Clin Immunol 1978;62:181-4.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Lin RY. A perspective on penicillin allergy. Arch Intern Med 1992;152:930-7.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Kelkar PS, Li JTC. Cephalosporin allergy. N Engl J Med 2001;345:804-9.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Lazaro JF, Gancedo SQ, Ruiz JP, de la Hoz Cabeller B, Rivas MF, Gonzalez ID, et al. Anaphylaxis to amoxycillin with good tolerance for other beta-lactam antibiotics. Rev Esp Alergol Immunol Clin 1991;5(3):151-4.
  5. 5.↵
    Sastre J, Quijano LD, Novalbos A, Hernandez G, Cuesta J, de las Heras M, et al. Clinical cross-reactivity between amoxicillin and cephadroxil in patients allergic to amoxicillin and with good tolerance of penicillin. Allergy 1996;51:383-6.
    OpenUrlPubMed
  6. 6.↵
    Novalbos A, Sastre J, Cuesta J, De Las Heras M, Lluch-Bernal M, Bombin C, et al. Lack of allergic cross-reactivity to cephalosporins among patients allergic to penicillins. Clin Exp Allergy 2001; 31:438-43.
    OpenUrlCrossRefPubMed
  7. 7.↵
    Ellis AK, Day JH. Anaphylaxis: diagnosis and management. CMAJ 2003;169(4):307-12.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 169 (11)
CMAJ
Vol. 169, Issue 11
25 Nov 2003
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Anaphylaxis treatment: the details
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Anaphylaxis treatment: the details
Anne K. Ellis, James H. Day
CMAJ Nov 2003, 169 (11) 1148-1149;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Anaphylaxis treatment: the details
Anne K. Ellis, James H. Day
CMAJ Nov 2003, 169 (11) 1148-1149;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The authors respond to letters on using prescribed psychostimulants to treat stimulant use disorder
  • Vigilance needed with methamphetamine-associated psychosis
  • Critical examination of incorporating prescription psychostimulants into the continuum of care for people with stimulant use disorder in Canada
Show more Letters

Similar Articles

Collections

  • Topics
    • Allergy

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire